Anebulo Pharmaceuticals, Inc.
ANEB- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815974
No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Anebulo Pharmaceuticals, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −2 vs. Q3 2025
- Shares held
- 22.2M
- −11.0K (0.0%) vs. Q3 2025
- Total value
- $6.81M
- −$48.7M (−87.7%) vs. Q3 2025
- New holders
- 2
- 6 more added
- Sold out
- 4
- 6 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANEB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 19 | $6.81M |
| Q3 2025 | 21 | $55.5M |
| Q2 2025 | 18 | $32.5M |
| Q1 2025 | 18 | $29.4M |
| Q4 2024 | 15 | $37.3M |
| Q3 2024 | 13 | $14.2M |
| Q2 2024 | 13 | $20.0M |
| Q1 2024 | 15 | $21.0M |
| Q4 2023 | 14 | $17.6M |
| Q3 2023 | 12 | $21.6M |
| Q2 2023 | 12 | $16.5M |
| Q1 2023 | 10 | $19.8M |
| Q4 2022 | 12 | $17.1M |
| Q3 2022 | 11 | $19.2M |
| Q2 2022 | 9 | $24.3M |
| Q1 2022 | 10 | $29.5M |
| Q4 2021 | 10 | $25.8M |
| Q3 2021 | 9 | $27.5M |
| Q2 2021 | 9 | $28.7M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Anebulo Pharmaceuticals, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 3,036,325 | $3.07M | 0.18% | 00.0% | Unchanged |
| Mangrove Partners | 2,525,252 | $2.55M | 0.21% | 00.0% | Unchanged |
| Vanguard Group Inc | 435,821 | $440.2K | 0.00% | +129,281+42.2% | Added |
| Morgan Stanley | 399,404 | $403.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 160,760 | $162.5K | 0.00% | −13,348−7.7% | Reduced |
| Rangeley Capital, LLC | 50,000 | $50.5K | 0.04% | +30,000+150.0% | Added |
| Renaissance Technologies LLC | 25,098 | $25.3K | 0.00% | −3,402−11.9% | Reduced |
| Citadel Advisors LLC | 24,239 | $24.5K | 0.00% | +24,239 | New |
| BlackRock, Inc. | 23,790 | $24.0K | 0.00% | −270−1.1% | Reduced |
| Northern Trust Corp | 21,994 | $22.2K | 0.00% | −2,399−9.8% | Reduced |
| Ikarian Capital, LLC | 17,736 | $17.9K | 0.00% | −139,984−88.8% | Reduced |
| State Street Corp | 12,768 | $12.9K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,230 | $3.26K | 0.00% | +1,480+84.6% | Added |
| UBS Group AG | 2,334 | $2.36K | 0.00% | +2,114+960.9% | Added |
| JPMorgan Chase & Co | 2,253 | $2.28K | 0.00% | +115+5.4% | Added |
| Bank of America Corp | 382 | $386 | 0.00% | −509−57.1% | Reduced |
| FNY Investment Advisers, LLC | 100 | $0 | 0.00% | +5+5.3% | Added |
| Royal Bank of Canada | 30 | $0 | 0.00% | +30 | New |
| 22NW, LP | 15,467,300 | – | – | 00.0% | Unchanged |
| XTX Topco Ltd | 0 | $0 | 0.00% | −19,153−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −18,836−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −399−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −6−100.0% | Sold out |